It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The development of site-specific recombinases (SSRs) as genome editing agents is limited by the difficulty of altering their native DNA specificities. Here we describe Rec-seq, a method for revealing the DNA specificity determinants and potential off-target substrates of SSRs in a comprehensive and unbiased manner. We applied Rec-seq to characterize the DNA specificity determinants of several natural and evolved SSRs including Cre, evolved variants of Cre, and other SSR family members. Rec-seq profiling of these enzymes and mutants thereof revealed previously uncharacterized SSR interactions, including specificity determinants not evident from SSR:DNA structures. Finally, we used Rec-seq specificity profiles to predict off-target substrates of Tre and Brec1 recombinases, including endogenous human genomic sequences, and confirmed their ability to recombine these off-target sequences in human cells. These findings establish Rec-seq as a high-resolution method for rapidly characterizing the DNA specificity of recombinases with single-nucleotide resolution, and for informing their further development.
The development of site-specific recombinases as genome editing tools is limited by the difficulty of altering their DNA sequence specificity. Here the authors present Rec-seq, a method for identifying specificity determinants and off-target substrates of recombinases in an unbiased manner.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Broad Institute of Harvard and MIT, Merkin Institute of Transformative Technologies in Healthcare, Cambridge, USA (GRID:grid.66859.34); Harvard University, Department of Chemistry and Chemical Biology, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard University, Howard Hughes Medical Institute, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
2 Broad Institute of Harvard and MIT, Chemical Biology and Therapeutics Science Program, Cambridge, USA (GRID:grid.66859.34)
3 Harvard University, Department of Chemistry and Chemical Biology, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard University, Howard Hughes Medical Institute, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
4 Google Inc., Mountain View, USA (GRID:grid.420451.6)